OSTX · OS Therapies Inc
$1.69
+0.03 (+1.81%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$76.57M
Shares
46.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.66
Open$1.68
Day$1.63–1.71
52W close$1.16–2.31
Avg vol 30d334K
Short int2.6M · 5.6% float · 9.1d
Short vol45%
DataAug 2024–Sep 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
+2%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
43%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+7%
trailing
YTD return
+19%
this year
Relative strength
−6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.60% of float · ▼ -6.9% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 2-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.60% of float · ▼ -6.9% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 43%
Range high $2
vs 200-day avg +5%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSTX
this stock
OS Therapies Inc
|
$76.57M | +18.6% | — | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSTX | +0.6% | +1.8% | +7.1% | -1.8% | +18.6% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | +1.2% | +3.1% | -5.5% | -1.1% | +6.9% |
Key facts
CIK
1795091
CUSIP
68764Y207
13F (30d)
27 filings
27 filers
Visit website
Investor relations